How to buy Talaris Therapeutics stock (Talaris Therapeutics)

Talaris Therapeutics is a biotechnology business based in the US. Talaris Therapeutics shares (TALS) are listed on the NASDAQ and all prices are listed in US Dollars. Talaris Therapeutics employs 84 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Talaris Therapeutics stock

Buy Talaris Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Talaris Therapeutics stock price (NASDAQ: TALS)

Use our graph to track the performance of TALS stocks over time.

Talaris Therapeutics shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$2.83
200-day moving average more info button	$2.44
Wall St. target price	$20.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.74

Is it a good time to buy Talaris Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Talaris Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-22.81%
Return on equity TTM	-41.64%
Profit margin	0%
Book value	$34.88
Market Capitalization more info button	$119.6 million

TTM: trailing 12 months

Talaris Therapeutics share dividends

We're not expecting Talaris Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Have Talaris Therapeutics's shares ever split?

Talaris Therapeutics's shares were split on a 1:10 basis on 19 October 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Talaris Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Talaris Therapeutics shares which in turn could have impacted Talaris Therapeutics's share price.

Talaris Therapeutics share price volatility

Over the last 12 months, Talaris Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Talaris Therapeutics's is 2.1789. This would suggest that Talaris Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Talaris Therapeutics's beta into context you can compare it against those of similar companies.

• Catalyst Pharmaceuticals (CPRX.US): 0.755
• Alnylam Pharmaceuticals (ALNY.US): 0.386
• Neurocrine Biosciences (NBIX.US): 0.353

Talaris Therapeutics overview

As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc. , in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients.

Frequently asked questions

What percentage of Talaris Therapeutics is owned by insiders or institutions?
Currently 11.91% of Talaris Therapeutics shares are held by insiders and 77.665% by institutions. How many people work for Talaris Therapeutics?
Latest data suggests 84 work at Talaris Therapeutics. When does the fiscal year end for Talaris Therapeutics?
Talaris Therapeutics's fiscal year ends in December. Where is Talaris Therapeutics based?
Talaris Therapeutics's address is: 570 South Preston Street, Louisville, KY, United States, 40202 What is Talaris Therapeutics's ISIN number?
Talaris Therapeutics's international securities identification number is: US87410C1045